Identification of Novel and Widely Expressed Cancer/Testis Gene Isoforms That Elicit Spontaneous Cytotoxic T-Lymphocyte Reactivity to Melanoma

Cancer Research

Volumn 64, Issue 3, 2004, Pages 1157-1163

  Hogan, Kevin T ^a,c   Coppola, Michael A ^c   Gatlin, Christine L ^c   Thompson, Lee W ^a   Shabanowitz, Jeffrey ^b   Hunt, Donald F ^a,b   Engelhard, Victor H ^b   Ross, Mark M ^c   Slingluff Jr , Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Upstate Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ARGINYLLEUCYLSERYLASPARAGINYLARGINYLLEUCYLLEUCYLLEUCYLARGININE; GENE PRODUCT; HLA A3 ANTIGEN; POLYPEPTIDE; TESTIS ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CHROMOSOME 5; CODON; CONTROLLED STUDY; GENE; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MELANOMA; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TAG1 GENE; TAG2A GENE; TAG2B GENE; TAG2C GENE; TESTIS; TUMOR ANTIGEN GENE; TUMOR CELL LINE; X CHROMOSOME;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-A3 ANTIGEN; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN ISOFORMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0842282547     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2209     Document Type: Article

References (35)

1. Van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
2. Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10: 281-287, 1999.
3. Castelli, C., Rivoltini, L., Andreola, G., Carrabba, M., Renkvist, N., and Parmiani, G. T-cell recognition of melanoma-associated antigens. J. Cell. Physiol., 182: 323-331, 2000.
4. Le Poole, I. C., Gerberi, M. A., and Kast, W. M. Emerging strategies in tumor vaccines. Curr. Opin. Oncol., 14: 641-648, 2002.
5. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. (Bethesda), 94: 805-818, 2002.
6. Weber, J. Peptide vaccines for cancer. Cancer Investig., 20: 208-221, 2002.
7. Ohnmacht, G. A., and Marincola, F. M. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J. Cell. Physiol., 182: 332-338, 2000.
8. Seliger, B., Maeurer, M. J., and Ferrone, S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 21: 455-464, 2000.
9. Slingluff, C. L., Jr., Colella, T. A., Thompson, L., Graham, D. D., Skipper, J. C., Caldwell, J., Brinckerhoff, L., Kittlesen, D. J., Deacon, D. H., Oei, C., Harthun, N. L., Huczko, E. L., Hunt, D. F., Darrow, T. L., and Engelhard, V. H. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol. Immunother., 48: 661-672, 2000.
10. Seliger, B., Cabrera, T., Garrido, F., and Ferrone, S. HLA class 1 antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol., 12: 3-13, 2002.
11. Skipper, J. C., Kittlesen, D. J., Hendrickson, R. C., Deacon, D. D., Harthun, N. L., Wagner, S. N., Hunt, D. F., Engelhard, V. H., and Slingluff, C. L., Jr. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol., 157: 5027-5033, 1996.
12. Lozzio, B. B., and Lozzio, C. B. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk. Res., 3: 363-370, 1979.
13. Greenberg, P. D., and Cheever, M. A. Treatment of established tumor by adoptive immunotherapy with specifically immune T cells. Surv. Immunol. Res., 4: 283-296, 1985.
14. Hogan, K. T., Eisinger, D. P., Cupp, S. B., III, Lekstrom, K. J., Deacon, D. D., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., Slingluff, C. L., Jr., and Ross, M. M. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res., 58: 5144-5150, 1998.
15. Berger, A. E., Davis, J. E., and Cresswell, P. Monoclonal antibody to HLA-A3. Hybridoma, 1: 87-90, 1982.
16. Shabanowitz, J., Settlage, R. E., Marto, J. A., Christian, R. E., White, F. M., Russo, P. S., Martin, S. E., and Hunt, D. F. Sequencing in the primordial soup. In: A. L. Burlingame, S. A. Carr, and M. A. Baldwin (eds.), Mass Spectrometry in Biology and Medicine, Ed. 1, pp. 163-177. Totowa, NJ: Humana Press, 2000.
17. Brickner, A. G., Warren, E. H., Caldwell, J. A., Akatsuka, Y., Golovina, T. N., Zarling, A. L., Shabanowitz, J., Eisenlohr, L. C., Hunt, D. F., Engelhard, V. H., and Riddell, S. R. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J. Exp. Med., 193: 195-206, 2001.
18. Hogan, K. T., Coppola, M. A., Gatlin, C. L., Thompson, L. W., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., Slingluff, C. L., Jr., and Ross, M. M. Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes. Immunol. Lett., 90: 131-135, 2003.
19. Zendman, A. J., de Wit, N. J., van Kraats, A. A., Weidle, U. H., Ruiter, D. J., and van Muijen, G. N. Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. Melanoma Res., 11: 451-459, 2001.
20. Zendman, A. J., Ruiter, D. J., and Van Muijen, G. N. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell. Physiol., 194: 272-288, 2003.
21. Yamshchikov, G., Thompson, L., Ross, W. G., Galavotti, H., Aquila, W., Deacon, D., Caldwell, J., Patterson, J. W., Hunt, D. F., and Slingluff, C. L., Jr. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin. Cancer Res., 7: 909s-916s, 2001.
22. Kirkin, A. F., Dzhandzhugazyan, K. N., and Zeuthen, J. Cancer/testis antigens: structural and immunobiological properties. Cancer Investig., 20: 222-236, 2002.
23. Wang, Z., Zhang, Y., Liu, H., Salati, E., Chiriva-Internati, M., and Lim, S. H. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood, 101: 955-960, 2003.
24. Chen, Y. T., and Old, L. J. Cancer-testis antigens: targets for cancer immunotherapy. Cancer J. Sci. Am., 5: 16-17, 1999.
25. Sprengart, M. L., and Porter, A. G. Functional importance of RNA interactions in selection of translation initiation codons. Mol. Microbiol., 24: 19-28, 1997.
26. Mayrand, S-M., and Green, W. R. Non-traditionally derived CTL epitopes: exceptions that prove the rules? Immunol. Today, 19: 551-555, 1998.
27. Shastri, N., Schwab, S., and Serwold, T. Producing nature's gene-chips: the generation of peptides for display by MHC class 1 molecules. Annu. Rev. Immunol., 20: 463-493, 2002.
28. Malarkannan, S., Afkarian, M., and Shastri, N. A rare cryptic translation product is presented by Kb major histocompatibility complex class 1 molecule to alloreactive T cells. J. Exp. Med., 182: 1739-1750, 1995.
29. Malarkannan, S., Horng, T., Shih, P. P., Schwab, S., and Shastri, N. Presentation of out-of-frame peptide/MHC class 1 complexes by a novel translation initiation mechanism. Immunity, 10: 681-690, 1999.
30. Ronsin, C., Chung-Scott, V., Poullion I., Aknouche, N., Gaudin, C., and Triebel, F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J. Immunol., 163: 483-490, 1999.
31. Dolstra, H., Fredrix, H., Maas, F., Coulie, P. G., Brasseur, F., Mensink, E., Adema, G. J., de Witte, T. M., Figdor, C. G., and van de Wiel-van Kemenade, E. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. Med., 189: 301-308, 1999.
32. Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA, 92: 7976-7980, 1995.
33. Guilloux, Y., Lucas, S., Brichard, V. G., Van Pel, A., Viret, C., De Plaen, E., Brasseur, F., Lethe, B., Jotereau, F., and Boon, T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med., 183: 1173-1183, 1996.
34. Robbins, P. F., El-Gamil, M., Li, Y. F., Fitzgerald, E. B., Kawakami, Y., and Rosenberg, S. A. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J. Immunol., 159: 303-308, 1997.
35. Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., and Traversari, C. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J. Exp. Med., 188: 1005-1016, 1998.